Rituximab as a Treatment Option for Refractory Endogenous Anterior Uveitis

Vol. 39, No. 3, 2007

Free Abstract Article (References) Article (PDF 105 KB)

Case Report

Rituximab as a Treatment Option for Refractory Endogenous Anterior Uveitis
C. Tappeiner^a, C. Heinz^a, C. Specker^b, A. Heiligenhaus^a

^aDepartment of Ophthalmology, St. Franziskus Hospital, Muenster, and
^bDepartment of Rheumatology and Immunology, Kliniken Essen-Sued, Essen, Germany

Address of Corresponding Author

Ophthalmic Res 2007;39:184-186 (DOI: 10.1159/000103239)

Key Words

Rituximab
Refractory endogenous anterior uveitis

Abstract

Background: To report on anti-CD20 antibody therapy in a patient with uveitis refractive to immunosuppression therapy. Methods: Case report with ophthalmoscopic, optical coherence tomography and fluorescein-angiographic findings. Results: A 49-year-old woman was suffering from bilateral, noninfectious chronic anterior uveitis refractive to corticosteroids and immunosuppressive drugs. Bilateral visual acuity was 20/100 due to cataract and cystoid macular edema (CME). After treatment with rituximab, vision and CME improved, and uveitis was stable until the final visit (follow-up at 12 months). Conclusion: The case report suggests that rituximab may be helpful for selected patients with chronic anterior uveitis refractive to corticosteroids and immunosuppressive medication.

Author Contacts

Prof. Dr. med. Arnd Heiligenhaus
Hohenzollernring 74
DE-48145 Münster (Germany)
Tel. +49 251 933 080, Fax +49 251 933 0819

Article Information

Received: September 13, 2006
Accepted after revision: December 6, 2006
Published online: May 25, 2007
Number of Print Pages : 3
Number of Figures : 1, Number of Tables : 0, Number of References : 9

Medline Abstract (ID 17534119)

Download Citation

Cited In

For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service.